Antibiofilm peptides increase the susceptibility of carbapenemase-producing Klebsiella pneumoniae clinical isolates to β-lactam antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 3906-3912

  Ribeiro, Suzana Meira ^a   De La Fuente Núñez, César ^b   Baquir, Beverlie ^b   Faria Junior, Célio ^c   Franco, Octávio L ^a,d   Hancock, Robert E W ^b  

^a UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Laboratório Central de Saúde Pública do Distrito Federal LACEN DF   (Brazil)

^d UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; DJK 5; DJK 6; ERTAPENEM; GENTAMICIN; IDR 1018; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; SYNTHETIC PEPTIDE; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; BACTERIAL PROTEIN; BETA LACTAM; BETA LACTAMASE; CARBAPENEMASE; CULTURE MEDIUM; PEPTIDE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ASSAY; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOFILM; CELL DEATH; CONTROLLED STUDY; ERADICATION THERAPY; HUMAN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; PLANKTON; PRIORITY JOURNAL; STATIC MICROPLATE ASSAY; ANTIBIOTIC RESISTANCE; CULTURE MEDIUM; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; GENETICS; KLEBSIELLA INFECTION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SYNTHESIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; BIOFILMS; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PEPTIDES;

EID: 84935881950     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00092-15     Document Type: Article

References (42)

1. Podschun R, Ullmann U. 1998. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 11:589-603.
2. Pagano L, Caira M, Trecarichi EM, Spanu T, Di Blasi R, Sica S, Sanguinetti M, Tumbarello M. 2014. Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis 20: 1235-1236. http://dx.doi.org/10.3201/eid2007.130094.
3. Dai Y, Zhang C, Ma X, Chang W, Hu S, Jia H, Huang J, Lu H, Li H, Zhou S, Qiu G, Liu J. 2014. Outbreak of carbapenemase-producing Klebsiella pneumoniae neurosurgical site infections associated with a contaminated shaving razor used for preoperative scalp shaving. Am J Infect Control 42:805-806. http://dx.doi.org/10.1016/j.ajic.2014.03.023.
4. Tuon FF, Rocha JL, Arend LN, Wallbach K, Zanin HA, Pilonetto M. 2013. Treatment and outcome of nine cases of KPC-producing Klebsiella pneumoniae meningitis. J Infect 67:161-164. http://dx.doi.org/10.1016/j.jinf.2013.04.003.
5. van Duin D, Cober E, Richter SS, Perez F, Kalayjian RC, Salata RA, Evans S, Fowler VG, Kaye KS, Bonomo RA. 2015. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70:1203-1211. http://dx.doi.org/10.1093/jac/dku495.
6. Chatterjee S, Maiti P, Dey R, Kundu A, Dey R. 2014. Biofilms on indwelling urologic devices: microbes and antimicrobial management prospect. Ann Med Health Sci Res 4:100-104. http://dx.doi.org/10.4103/2141-9248.126612.
7. Song C, Yu J, Ai Q, Liu D, Lu W, Lu Q, Peng N. 2013. Diversity analysis of biofilm bacteria on tracheal tubes removed from intubated neonates. Zhonghua Er Ke Za Zhi 51:602-606. (In Chinese.)
8. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, Segre JA. 2012. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 4:148ra116. http://dx.doi.org/10.1126/scitranslmed.3004129.
9. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, Schlaeffer F, Sherf M. 2009. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 30:972-976. http://dx.doi.org/10.1086/605922.
10. McKenna M. 2013. Antibiotic resistance: the last resort. Nature 499:394-396. http://dx.doi.org/10.1038/499394a.
11. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. 2009. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 30: 1180-1185. http://dx.doi.org/10.1086/648451.
12. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108-2113. http://dx.doi.org/10.1128/AAC.06268-11.
13. Hirsch EB, Tam VH. 2010. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65:1119-1125. http://dx.doi.org/10.1093/jac/dkq108.
14. Spanu T, Angelis GD, Cipriani M, Pedruzzi B, D'Inzeo T, Cataldo MA, Sganga G, Tacconelli E. 2012. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 56:4516-4518. http://dx.doi.org/10.1128/AAC.00234-12.
15. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E, Sofianou D. 2010. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin. J Hosp Infect 76:70-73. http://dx.doi.org/10.1016/j.jhin.2010.03.021.
16. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside modifying enzymes, which exert varying effects on plazomicin and other agents. Antimicrob Agents Chemother 58:4443-4451. http://dx.doi.org/10.1128/AAC.00099-14.
17. de la Fuente-Núñez C, Reffuveille F, Fernández L, Hancock REW. 2013. Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 16:580-589. http://dx.doi.org/10.1016/j.mib.2013.06.013.
18. st ed. Springer, London, England.
19. Roy S, Elgharably H, Sinha M, Ganesh K, Chaney S, Mann E, Miller C, Khanna S, Bergdall VK, Powell HM, Cook CH, Gordillo GM, Wozniak DJ, Sen CK. 2014. Mixed-species biofilm compromises wound healing by disrupting epidermal barrier function. J Pathol 233:331-343. http://dx.doi.org/10.1002/path.4360.
20. Bjarnsholt T. 2013. The role of bacterial biofilms in chronic infections. APMIS Suppl 2013(136):1-51.
21. Lanter BB, Sauer K, Davies DG. 2014. Bacteria present in carotid arterial plaques are found as biofilm deposits which may contribute to enhanced risk of plaque rupture. mBio 5:e01206-14. http://dx.doi.org/10.1128/mBio.01206-14.
22. Jung C-J, Yeh C-Y, Shun C-T, Hsu R-B, Cheng H-W, Lin C-S, Chia J-S. 2012. Platelets enhance biofilm formation and resistance of endocarditis-inducing streptococci on the injured heart valve. J Infect Dis 205:1066-1075. http://dx.doi.org/10.1093/infdis/jis021.
23. Abidi SH, Sherwani SK, Siddiqui TR, Bashir A, Kazmi SU. 2013. Drug resistance profile and biofilm forming potential of Pseudomonas aeruginosa isolated from contact lenses in Karachi-Pakistan. BMC Ophthalmol 13:57. http://dx.doi.org/10.1186/1471-2415-13-57.
24. Vandecandelaere I, Matthijs N, Van Nieuwerburgh F, Deforce D, Vosters P, De Bus L, Nelis HJ, Depuydt P, Coenye T. 2012. Assessment of microbial diversity in biofilms recovered from endotracheal tubes using culture dependent and independent approaches. PLoS One 7:e38401. http://dx.doi.org/10.1371/journal.pone.0038401.
25. Pour NK, Dusane DH, Dhakephalkar PK, Zamin FR, Zinjarde SS, Chopade BA. 2011. Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol Med Microbiol 62:328-338. http://dx.doi.org/10.1111/j.1574-695X.2011.00818.x.
26. Römling U, Kjelleberg S, Normark S, Nyman L, Uhlin BE, Åkerlund B. 2014. Microbial biofilm formation: a need to act. J Intern Med 276:98-110. http://dx.doi.org/10.1111/joim.12242.
27. Fjell CD, Hiss JA, Hancock REW, Schneider G. 2012. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11:37-51. http://dx.doi.org/10.1038/nrd3591.
28. de la Fuente-Núñez C, Reffuveille F, Haney EF, Straus SK, Hancock REW. 2014. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog 10:e1004152. http://dx.doi.org/10.1371/journal.ppat.1004152.
29. de la Fuente-Núñez C, Korolik V, Bains M, Nguyen U, Breidenstein EBM, Horsman S, Lewenza S, Burrows L, Hancock REW. 2012. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother 56:2696-2704. http://dx.doi.org/10.1128/AAC.00064-12.
30. Overhage J, Campisano A, Bains M, Torfs ECW, Rehm BHA, Hancock REW. 2008. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76:4176-4182. http://dx.doi.org/10.1128/IAI.00318-08.
31. Reffuveille F, de la Fuente-Núñez C, Mansour S, Hancock REW. 2014. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother 58:5363-5371. http://dx.doi.org/10.1128/AAC.03163-14.
32. de la Fuente-Núñez C, Reffuveille F, Mansour SC, Reckseidler-Zenteno SL, Hernández D, Brackman G, Coenye T, Hancock REW. 2015. D-Enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem Biol 22:196-205. http://dx.doi.org/10.1016/j.chembiol.2015.01.002.
33. th ed. ASM Press, Washington, DC.
34. th ed. CLSI document M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
35. Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, Carey RB, Thompson A, Stocker S, Limbago B, Patel JB. 2007. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 45:2723-2725. http://dx.doi.org/10.1128/JCM.00015-07.
36. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. 2001. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151-1161. http://dx.doi.org/10.1128/AAC.45.4.1151-1161.2001.
37. Wiegand I, Hilpert K, Hancock REW. 2008. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3:163-175. http://dx.doi.org/10.1038/nprot.2007.521.
38. Hindré T, Brüggemann H, Buchrieser C, Héchard Y. 2008. Transcriptional profiling of Legionella pneumophila biofilm cells and the influence of iron on biofilm formation. Microbiology 154:30-41. http://dx.doi.org/10.1099/mic.0.2007/008698-0.
39. Mulcahy H, Lewenza S. 2011. Magnesium limitation is an environmental trigger of the Pseudomonas aeruginosa biofilm lifestyle. PLoS One 6:e23307. http://dx.doi.org/10.1371/journal.pone.0023307.
40. Allan VJM, Callow ME, Macaskie LE, Paterson-Beedle M. 2002. Effect of nutrient limitation on biofilm formation and phosphatase activity of a Citrobacter sp. Microbiology 148:277-288.
41. Chen L, Chavda KD, Melano RG, Hong T, Rojtman AD, Jacobs MR, Bonomo RA, Kreiswirth BN. 2014. Molecular survey of the dissemination of two blaKPC-harboring IncFIA plasmids in New Jersey and New York hospitals. Antimicrob Agents Chemother 58:2289-2294. http://dx.doi.org/10.1128/AAC.02749-13.
42. Haisma EM, Breij A de, Chan H, Dissel JT van, Drijfhout JW, Hiemstra PS, Ghalbzouri AE, Nibbering PH. 2014. LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents. Antimicrob Agents Chemother 58:4411-4419. http://dx.doi.org/10.1128/AAC.02554-14.